Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

J. Ezaki



Author of

  • +

    P1.06 - Poster Session 1 - Prognostic and Predictive Biomarkers (ID 161)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Biology
    • Presentations: 1
    • +

      P1.06-024 - FAM83B, a novel molecular target for lung squamous cell carcinoma. (ID 1869)

      09:30 - 09:30  |  Author(s): J. Ezaki

      • Abstract

      Background
      Recently, personalize therapy for non-small cell lung cancer (NSCLC) has been improving and significantly to extract various molecular target. However, development of molecular targeted drugs is proceeding only in lung adenocarcinoma to date, while there are few drugs for lung squamous cell carcinoma (SCC). Therefore, we tried to extract molecular targets for SCC by comprehensive gene expression analysis of clinical specimen.

      Methods
      The subjects of this study consisted of 215 patients with NSCLC who underwent complete resection since 2005 to 2011 in our hospital. They included 102 adenocarcinomas and 113 SCC. First, we tried to extract molecules specific to SCC by tissue array analysis of clinical specimen. We selected FAM83B as a candidate marker for SCC by using comprehensive gene expression analysis. Then, we examined the protein expression of FAM83B in NSCLC tissues by immunoblot and immunohistochemical analysis (IHC). The relationship between the FAM83B expression and clinic-pathological factors was statistically analyzed.

      Results
      FAM83B expression at mRNA level was significantly higher in SCC than in normal lung or adenocarcinoma (P<0.0001). Immunoblot analysis also confirmed this tendency. In IHC, FAM83B was diffusely localized in the cytoplasm and/or plasma membrane. When more than 10% positive area for FAM83B were judged as “positive”, 94.3% (107/113) of SCC and 14.7% (15/102), of adenocarcinoma were positive. If the patients were divided into two subgroups by IHC (54 high-expression patients and 53 low-expression patients), high-expression group was associated with a better disease free survival rate (P=0.042, log-rank test). Figure 1

      Conclusion
      Our results indicated that FAM83B could be a reliable diagnostic and prognostic biomarker for SCC. Biological function of FAM83B in lung cancer is not well known. Further analyses should be required to identify its clinical significance and biological function.